A review of the clinical efficacy of FDA-approved antibody‒drug conjugates in human cancers

A review of the clinical efficacy of FDA-approved antibody‒drug conjugates in human cancers

Abstract While strategies such as chemotherapy and immunotherapy have become the first-line standard therapies for patients with advanced or metastatic cancer, acquired resistance is still inevitable in most cases. The introduction of antibody‒drug conjugates (ADCs) provides a novel alternative. ADC...

Full description

Bibliographic Details
Main Authors: Kaifeng Liu, Meijia Li, Yudong Li, Yutong Li, Zixin Chen, Yiqi Tang, Meitian Yang, Guoquan Deng, Hongwei Liu
Format: Article
Language:English
Published: BMC 2024-03-01
Series:Molecular Cancer
Subjects:
Antibody‒drug conjugates
Cancer therapy
Targeted drugs
FDA‒approved
Clinical efficacy
Online Access:https://doi.org/10.1186/s12943-024-01963-7

Internet

https://doi.org/10.1186/s12943-024-01963-7

Similar Items